{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:57:22Z","timestamp":1780491442191,"version":"3.54.1"},"reference-count":147,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Venous thromboembolism (VTE) is an important aspect in cancer patients. There are various pharmacological methods used for thrombotic event treatment. DOACs (direct-acting oral anticoagulants) are gaining popularity among both physicians and researchers and are slowly starting to replace VKAs (vitamin K antagonists), thus becoming a substitute or alternative option for LMWHs (low-molecular-weight heparins). In this article, we present DOACs\u2019 main therapeutic advantages and disadvantages in patients with cancer. The only major concern with using DOACs is the higher risk of bleeding; however, there are discrepancies in this matter. There are still some types of cancer for which DOACs are not recommended. Specific cancer types may influence the efficacy of DOAC therapy. Additionally, race and ethnicity may affect therapy in cancer patients with DOACs. A sizeable number of clinical trials are focused on comparing DOACs with other anticoagulants. The current guidelines of different scientific associations are not unanimous in their DOAC assessments. There is still a need for more evidence of DOACs\u2019 potential advantages over other methods of anticoagulation in cancer patients to facilitate their position in this recommendation. This literature review presents the current state of knowledge about the use of DOACs in patients with neoplastic growth.<\/jats:p>","DOI":"10.3390\/cancers15102697","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T01:37:24Z","timestamp":1683769044000},"page":"2697","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Direct-Acting Oral Anticoagulant Therapy in Cancer Patients\u2014A Review"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7277-8036","authenticated-orcid":false,"given":"Tomasz","family":"G\u00f3rnicki","sequence":"first","affiliation":[{"name":"Student Research Club No. 180, Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland"},{"name":"Division of Histology and Embryology, Department of Human Morphology and Embryology, Wroclaw Medical University, 50-368 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4933-9198","authenticated-orcid":false,"given":"Kacper","family":"Bu\u0142dy\u015b","sequence":"additional","affiliation":[{"name":"Student Research Club No. 180, Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Zieli\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Surgery, 4th Military Teaching Hospital, 50-981 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9232-4525","authenticated-orcid":false,"given":"Mariusz","family":"Chabowski","sequence":"additional","affiliation":[{"name":"Department of Surgery, 4th Military Teaching Hospital, 50-981 Wroclaw, Poland"},{"name":"Division of Anesthesiological and Surgical Nursing, Department of Nursing and Obstetrics, Faculty of Health Science, Wroclaw Medical University, 51-618 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: A population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Pastori, D., Cormaci, V.M., Marucci, S., Franchino, G., Del Sole, F., Capozza, A., Fallarino, A., Corso, C., Valeriani, E., and Menichelli, D. (2023). A Comprehensive Review of Risk Factors for Venous Thromboembolism: From Epidemiology to Pathophysiology. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043169"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1055\/s-0041-1726298","article-title":"Single, dual, and triple antithrombotic therapy in cancer patients with coronary artery disease: Searching for evidence and personalized approaches","volume":"Volume 47","author":"Santoro","year":"2021","journal-title":"Seminars in Thrombosis and Hemostasis"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.7150\/thno.80555","article-title":"Platelets promote CRC by activating the C5a\/C5aR1 axis via PSGL-1\/JNK\/STAT1 signaling in tumor-associated macrophages","volume":"13","author":"Li","year":"2023","journal-title":"Theranostics"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.thromres.2016.01.006","article-title":"Role of platelets in cancer and cancer-associated thrombosis: Experimental and clinical evidences","volume":"139","author":"Mezouar","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.thromres.2017.09.019","article-title":"Breast-cancer extracellular vesicles induce platelet activation and aggregation by tissue factor-independent and -dependent mechanisms","volume":"159","author":"Gomes","year":"2017","journal-title":"Thromb. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1110352","article-title":"Paraneoplastic thrombocytosis in ovarian cancer","volume":"366","author":"Stone","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1182\/blood.V80.8.2052.2052","article-title":"Thrombocytosis in patients with tumors producing colony-stimulating factor","volume":"80","author":"Suzuki","year":"1992","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1055\/s-0039-1693475","article-title":"Involvement of Platelets in Cancers","volume":"Volume 45","author":"Mege","year":"2019","journal-title":"Seminars in Thrombosis and Hemostasis"},{"key":"ref_10","first-page":"2401","article-title":"New oral anticoagulants\u2014Possible extension to other indications (Review)","volume":"20","author":"Laslo","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"259","DOI":"10.5853\/jos.2019.01970","article-title":"Non-Vitamin K Antagonist Oral Anticoagulants in Medical Conditions at High Risk of Thromboembolism beyond Atrial Fibrillation","volume":"21","author":"Hong","year":"2019","journal-title":"J. Stroke"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1160\/TH16-10-0807","article-title":"New developments in anticoagulants: Past, present and future","volume":"117","author":"Weitz","year":"2017","journal-title":"Thromb. Haemost."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12959-016-0111-3","article-title":"DOACs\u2014Advances and limitations in real world","volume":"14","author":"Lee","year":"2016","journal-title":"Thromb. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e743","DOI":"10.1097\/FJC.0000000000001112","article-title":"Nonvitamin K Antagonist Oral Anticoagulant in Patients With Venous Thromboembolism and Polycythemia Vera or Essential Thrombocythemia: A Cohort Study","volume":"78","author":"Weronska","year":"2021","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1182\/bloodadvances.2019000462","article-title":"Patient values and preferences regarding VTE disease: A systematic review to inform American Society of Hematology guidelines","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.3324\/haematol.2015.127126","article-title":"Assessing patients\u2019 anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology","volume":"100","author":"Noble","year":"2015","journal-title":"Haematologica"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1080\/14779072.2020.1822167","article-title":"Cancer-associated venous thromboembolism and the non-vitamin K antagonist oral anticoagulants: A review of clinical outcomes and patient perspectives","volume":"18","author":"Overvad","year":"2020","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1177\/0269216318815377","article-title":"Oral anticoagulation is preferable to injected, but only if it is safe and effective: An interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial","volume":"33","author":"Hutchinson","year":"2019","journal-title":"Palliat. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1055\/s-0040-1714739","article-title":"Anticoagulation Treatment in Cancer-Associated Venous Thromboembolism: Assessment of Patient Preferences Using a Discrete Choice Experiment (COSIMO Study)","volume":"121","author":"Picker","year":"2021","journal-title":"Thromb. Haemost."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"675969","DOI":"10.3389\/fcvm.2021.675969","article-title":"Patient Characteristics and Preferences Regarding Anticoagulant Treatment in Venous Thromboembolic Disease","volume":"8","author":"Mauger","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"209S","DOI":"10.1177\/1076029618804080","article-title":"Venous Thromboembolism: A Survey of Oral Anticoagulant Preferences in the Treatment of Challenging Patient Populations","volume":"24","author":"Moyer","year":"2018","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/phar.2158","article-title":"Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010\u20132017","volume":"38","author":"Zhu","year":"2018","journal-title":"Pharmacotherapy"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4103\/ija.IJA_734_18","article-title":"Novel reversal agents and laboratory evaluation for direct-acting oral anticoagulants (DOAC): An update","volume":"63","author":"Shah","year":"2019","journal-title":"Indian J. Anaesth."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"67","DOI":"10.5334\/gh.774","article-title":"NOACs Added to WHO\u2019s Essential Medicines List: Recommendations for Future Policy Actions","volume":"15","author":"Jarvis","year":"2020","journal-title":"Global Heart"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1021\/jm050101d","article-title":"Discovery of the novel antithrombotic agent 5-chloro-N-([(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1, 3-oxazolidin-5-yl]methyl)thiophene-2-carboxamide (BAY 59\u20137939): An oral, direct Factor Xa inhibitor","volume":"48","author":"Roehrig","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.thromres.2010.09.008","article-title":"The mechanism of action of rivaroxaban-an oral, direct Factor Xa inhibitor-Compared with other anticoagulants","volume":"127","author":"Samama","year":"2011","journal-title":"Thromb. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clpt.2005.06.011","article-title":"Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor","volume":"78","author":"Kubitza","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_28","unstructured":"European Medicines Agency: Xarelto (2023, February 27). European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xarelto#authorisation-details-section."},{"key":"ref_29","unstructured":"Janssen Pharmaceuticals, Inc (2023, February 17). Xarelto (Rivaroxaban) Prescribing Information. Revised 02\/2023. Available online: https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/XARELTO-pi.pdf."},{"key":"ref_30","unstructured":"(2023, April 17). Xarelto: EPAR-Product Information. Last Updated 23\/02\/2023. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/xarelto-epar-medicine-overview_en.pdf."},{"key":"ref_31","unstructured":"Agrawal, A., Kerndt, C.C., and Manna, B. (2022). Apixaban, StatPearls Publishing."},{"key":"ref_32","unstructured":"European Medicines Agency: Eliquis (2023, February 27). European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/eliquis."},{"key":"ref_33","unstructured":"(2023, April 17). Eliquis Prescribing Information. Revised 04\/2021, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/202155s032lbl.pdf."},{"key":"ref_34","unstructured":"(2023, April 17). Eliquis: EPAR-Product Information. Last Updated 09\/09\/2022. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/eliquis-epar-product-information_en.pdf."},{"key":"ref_35","unstructured":"Padda, I.S., and Chowdhury, Y.S. (2022). Chowdhury. Edoxaban, StatPearls Publishing."},{"key":"ref_36","unstructured":"European Medicines Agency: Lixiana (2023, February 27). European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lixiana."},{"key":"ref_37","unstructured":"(2023, April 17). Savaysa Prescribing Information. Revised 01\/2015, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206316lbl.pdf."},{"key":"ref_38","unstructured":"(2023, April 17). Lixiana: EPAR-Product Information. Last Updated 23\/04\/2021. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lixiana-epar-product-information_en.pdf."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Schwarb, H., and Tsakiris, D.A. (2016). New Direct Oral Anticoagulants (DOAC) and Their Use Today. Dent. J., 4.","DOI":"10.3390\/dj4010005"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.clinthera.2012.09.008","article-title":"Dabigatran in clinical practice","volume":"34","author":"Nagarakanti","year":"2012","journal-title":"Clin. Ther."},{"key":"ref_41","unstructured":"European Medicines Agency: Pradaxa (2023, February 28). European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/pradaxa."},{"key":"ref_42","unstructured":"(2023, April 17). Pradaxa Prescribing Information. Revised 06\/2021, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214358s000lbl.pdf."},{"key":"ref_43","unstructured":"(2023, April 17). Pradaxa: EPAR-Product Information. Last Updated 25\/07\/2022. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/pradaxa-epar-product-information_en.pdf."},{"key":"ref_44","unstructured":"Bennett, P.N., Brown, M.J., and Sharma, P. (2012). Clinical Pharmacology, Churchill Livingstone. [11th ed.]."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12959-017-0156-y","article-title":"NOACs replace VKA as preferred oral anticoagulant among new patients: A drug utilization study in 560 pharmacies in The Netherlands","volume":"16","year":"2018","journal-title":"Thromb. J."},{"key":"ref_46","first-page":"1341","article-title":"Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: Insights from a specialist atrial fibrillation clinic","volume":"69","author":"Lee","year":"2015","journal-title":"Int. J. Clin."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"101861","DOI":"10.1016\/j.pmedr.2022.101861","article-title":"Preferences for and use of oral anticoagulants for stroke prevention in atrial fibrillation under real-world conditions in Germany: A survey among physicians","volume":"28","author":"Mocek","year":"2022","journal-title":"Prev. Med. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/5584_2016_112","article-title":"The Role of New Oral Anticoagulants (NOACs) in Cancer Patients","volume":"906","author":"Ravikumar","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1378\/chest.14-0402","article-title":"Direct oral anticoagulants in patients with VTE and cancer: A systematic review and meta-analysis","volume":"147","author":"Vedovati","year":"2015","journal-title":"Chest"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Larsen, T.B., Nielsen, P.B., Skj\u00f8th, F., Rasmussen, L.H., and Lip, G.Y. (2014). Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: A semi systematic review and meta-analysis of safety and efficacy outcomes. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0114445"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/jth.12605","article-title":"Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism","volume":"12","author":"Kooiman","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1055\/a-0955-3379","article-title":"Antithrombotische Therapie bei Lungenembolie [Antithrombotic Treatment of Pulmonary Embolism]","volume":"145","author":"Ebner","year":"2020","journal-title":"Dtsch. Med. Wochenschr."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3389\/fphar.2018.00575","article-title":"Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants for Venous Thromboembolism Prophylaxis in Patients with Cancer: A Systematic Review and Trade-Off Analysis from 9 Randomized Controlled Trials","volume":"9","author":"Yan","year":"2018","journal-title":"Front Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e13773","DOI":"10.1111\/eci.13773","article-title":"Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EURObservational research programme in atrial fibrillation general long-term registry","volume":"52","author":"Malavasi","year":"2022","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.2147\/DDDT.S373726","article-title":"New Oral Anticoagulants Open New Horizons for Cancer Patients with Venous Thromboembolism","volume":"16","author":"Wumaier","year":"2022","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1076029620940046","DOI":"10.1177\/1076029620940046","article-title":"The Net Clinical Benefit of Rivaroxaban Compared to Low-Molecular-Weight Heparin in the Treatment of Cancer-Associated Thrombosis: Systematic Review and Meta-Analysis","volume":"27","author":"Mohamed","year":"2021","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1076029619846562","DOI":"10.1177\/1076029619846562","article-title":"Quality Appraisal of Guidelines on Cancer-Associated Thrombosis Using AGREE II Instrument and Analysis of Current Status of New Oral Anticoagulants","volume":"25","author":"Zhang","year":"2019","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2147\/TCRM.S84210","article-title":"New oral anticoagulants: Their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events","volume":"11","author":"Mekaj","year":"2015","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3904\/kjim.2017.415","article-title":"A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: A comparison study of Drugs for symptom control and complication prevention of Atrial Fibrillation (CODE-AF)","volume":"35","author":"Kim","year":"2020","journal-title":"Korean J. Intern. Med."},{"key":"ref_61","first-page":"5026","article-title":"Venous thromboembolism in cancer patients: Still looking for answers","volume":"18","author":"Iorga","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1177\/1060028020960037","article-title":"Direct Oral Anticoagulant for the Treatment of VTE in Cancer Patients: A Systematic Review and Meta-analysis","volume":"55","author":"Dong","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.1016\/S2352-3026(16)30057-6","article-title":"Edoxaban for venous thromboembolism in patients with cancer: Results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial","volume":"3","author":"Raskob","year":"2016","journal-title":"Lancet Haematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1053\/j.seminoncol.2016.11.009","article-title":"The use of novel oral anticoagulants in cancer patients with venous thromboembolism","volume":"43","author":"Karakatsanis","year":"2016","journal-title":"Semin. Oncol."},{"key":"ref_65","first-page":"689","article-title":"Efficacy and safety of non-vitamin K antagonist versus vitamin K antagonist oral anticoagulants in the prevention and treatment of thrombotic disease in active cancer patients: A systematic review and meta-analysis of randomized controlled trials","volume":"48","author":"Wang","year":"2020","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s11739-015-1233-5","article-title":"Pros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancer","volume":"10","author":"Verso","year":"2015","journal-title":"Intern. Emerg. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1055\/s-0042-1757744","article-title":"On-treatment Comparative Effectiveness of Vitamin K Antagonists and Direct Oral Anticoagulants in GARFIELD-VTE, and Focus on Cancer and Renal Disease","volume":"6","author":"Haas","year":"2022","journal-title":"TH Open"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"101346","DOI":"10.1016\/j.cpcardiol.2022.101346","article-title":"Efficacy and Safety of the Non-Vitamin K Antagonist Oral Anticoagulant Among Patients with Nonvalvular Atrial Fibrillation and Cancer: A Systematic Review and Network Meta-analysis","volume":"47","author":"Barbarawi","year":"2022","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1161\/STROKEAHA.120.033470","article-title":"Clinical Outcomes in Atrial Fibrillation Patients with a History of Cancer Treated with Non-Vitamin K Antagonist Oral Anticoagulants: A Nationwide Cohort Study","volume":"52","author":"Chan","year":"2021","journal-title":"Stroke"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3109\/07853890.2014.952327","article-title":"Anticoagulant-related gastrointestinal bleeding--could this facilitate early detection of benign or malignant gastrointestinal lesions?","volume":"46","author":"Clemens","year":"2014","journal-title":"Ann. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.hjc.2020.11.007","article-title":"Association of anticoagulant-related bleeding events with cancer detection in atrial fibrillation: A systematic review and meta-analysis","volume":"62","author":"Papanastasiou","year":"2021","journal-title":"Hell. J. Cardiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.hrthm.2020.05.026","article-title":"Risks and outcomes of gastrointestinal malignancies in anticoagulated atrial fibrillation patients experiencing gastrointestinal bleeding: A nationwide cohort study","volume":"17","author":"Chang","year":"2020","journal-title":"Heart Rhythm."},{"key":"ref_73","first-page":"33","article-title":"New Oral Anticoagulants (NOACs) are The Gold Standard Invenous Thromboembolism","volume":"27","author":"Antunes","year":"2020","journal-title":"Rev. Port. Cir. Cardiotorac. Vasc."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.2147\/RMHP.S306760","article-title":"Clinical Benefits of Oral Anticoagulant Use in Cancer Patients at Increased Risk for Venous Thromboembolism per Khorana Index","volume":"14","author":"Choi","year":"2021","journal-title":"Risk Manag. Healthc. Policy"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00228-021-03132-x","article-title":"Safety and efficacy of new oral anticoagulants compared to those of warfarin in AF patients with cancer: A meta-analysis of randomized clinical trials and observational studies","volume":"77","author":"Chen","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"92","DOI":"10.7150\/jca.36468","article-title":"Novel Oral Anticoagulant versus Warfarin in Cancer Patients with Atrial Fibrillation: An 8-Year Population-Based Cohort Study","volume":"11","author":"Wu","year":"2020","journal-title":"J. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4070\/kcj.2017.0328","article-title":"Effect of Non-vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Newly Diagnosed Cancer","volume":"48","author":"Kim","year":"2018","journal-title":"Korean Circ. J."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/joim.13092","article-title":"Use of oral anticoagulants after ischemic stroke in patients with atrial fibrillation and cancer","volume":"288","author":"Atterman","year":"2020","journal-title":"J. Intern. Med."},{"key":"ref_79","unstructured":"Solari, F., and Varacallo, M. (2018). Low Molecular Weight Heparin (LMWH), StatPearls Publishing."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1124\/pr.115.011247","article-title":"Pharmacology of Heparin and Related Drugs","volume":"68","author":"Mulloy","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/17476348.2018.1452614","article-title":"Non-vitamin K antagonist oral anticoagulants for pulmonary embolism: Who, where and for how long?","volume":"12","author":"Howard","year":"2018","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1634\/theoncologist.2013-0239","article-title":"New oral anticoagulants and the cancer patient","volume":"19","author":"Short","year":"2014","journal-title":"Oncologist"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"D293","DOI":"10.1093\/eurheartj\/sux026","article-title":"ANMCO Position Paper: The use of non-vitamin K dependent new oral anticoagulant(s) in pulmonary embolism therapy and prevention","volume":"19","author":"Enea","year":"2017","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Al-Samkari, H., and Connors, J.M. (2018). The Role of Direct Oral Anticoagulants in Treatment of Cancer-Associated Thrombosis. Cancers, 10.","DOI":"10.3390\/cancers10080271"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"106567","DOI":"10.1016\/j.vph.2019.106567","article-title":"Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study","volume":"120","author":"Stepien","year":"2019","journal-title":"Vascul. Pharmacal."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijcard.2022.04.068","article-title":"Pulmonary embolism in patients with cancer: An updated and operative guide for diagnosis and management","volume":"358","author":"Tirandi","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"ref_87","first-page":"2","article-title":"Management of atrial fibrillation in patients taking targeted cancer therapies","volume":"3","author":"Asnani","year":"2017","journal-title":"Cardiooncology"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Jin, C., Cui, C., Seplowe, M., Lee, K.I., Vegunta, R., Li, B., Frishman, W.H., and Iwai, S. (2022). Anticoagulation for Atrial Fibrillation: A Review of Current Literature and Views. Cardiol. Rev.","DOI":"10.1097\/CRD.0000000000000489"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: Second update of the CHEST guideline and expert panel report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ygyno.2020.11.020","article-title":"Direct oral anticoagulant use in gynecologic oncology: A Society of Gynecologic Oncology Clinical Practice Statement","volume":"160","author":"Gressel","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Ren, J.W., Zheng, X., and Han, X.H. (2023). Generic Methods for Simultaneous Analysis of Four Direct Oral Anticoagulants in Human Plasma and Urine by Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry. Molecules, 28.","DOI":"10.3390\/molecules28052254"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jaccao.2019.11.007","article-title":"Proceedings from the Global Cardio-Oncology Summit: The Top 10 Priorities to Actualize for CardioOncology","volume":"1","author":"Lenihan","year":"2019","journal-title":"JACC CardioOncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer: ASCO Clinical Practice Guideline Update","volume":"38","author":"Key","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline","volume":"34","author":"Falanga","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_96","first-page":"1181","article-title":"Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Streiff","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: Prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv."},{"key":"ref_98","first-page":"CD010957","article-title":"Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism","volume":"4","author":"Li","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"100115","DOI":"10.1016\/j.rpth.2023.100115","article-title":"Risk of recurrent cancer-associated thrombosis after discontinuation of anticoagulant therapy","volume":"7","author":"Carrier","year":"2023","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Debourdeau, P., Bertoletti, L., Font, C., L\u00f3pez-N\u00fa\u00f1ez, J.J., G\u00f3mez-Cuervo, C., Mahe, I., Otero-Candelera, R., Adarraga, M.D., L\u00f3pez-Miguel, P., and Monreal, M. (2023). Three-Month Outcomes in Cancer Patients with Superficial or Deep Vein Thrombosis in the Lower Limbs: Results from the RIETE Registry. Cancers, 15.","DOI":"10.3390\/cancers15072034"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s11239-023-02791-0","article-title":"Direct oral anticoagulants in patients with venous thromboembolism and hematological malignancies","volume":"55","author":"Robinson","year":"2023","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.thromres.2023.02.010","article-title":"Unreported incidental pulmonary embolism in patients with cancer: Radiologic natural history and risk of recurrent venous thromboembolism and death","volume":"224","author":"Wiklund","year":"2023","journal-title":"Thromb. Res."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Vedovati, M.C., Giustozzi, M., Munoz, A., Bertoletti, L., Cohen, A.T., Klok, F.A., Connors, J.M., Bauersachs, R., Brenner, B., and Campanini, M. (2023). Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism. Eur. J. Intern. Med., ahead of print.","DOI":"10.1016\/j.ejim.2023.02.003"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.thromres.2018.02.144","article-title":"Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis","volume":"173","author":"Li","year":"2019","journal-title":"Thromb. Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e17894","DOI":"10.1097\/MD.0000000000017894","article-title":"The anticoagulants rivaroxaban and low molecular weight heparin prevent PICC-related upper extremity venous thrombosis in cancer patients","volume":"98","author":"Lv","year":"2019","journal-title":"Medicine"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"10760296221132556","DOI":"10.1177\/10760296221132556","article-title":"Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial: Venous thromboembolism prophylAxis after gynecoLogical pElvic cancer surgery with RIvaroxaban versus enoxAparin (VALERIA trial)","volume":"28","author":"Agati","year":"2022","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e2036304","DOI":"10.1001\/jamanetworkopen.2020.36304","article-title":"Comparison between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism","volume":"4","author":"Chen","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2147\/VHRM.S132556","article-title":"Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients","volume":"15","author":"Song","year":"2019","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"103074","DOI":"10.1016\/j.critrevonc.2020.103074","article-title":"Efficacy and safety of novel oral anticoagulants versus low molecular weight heparin in cancer patients with venous thromboembolism: A systematic review and meta-analysis","volume":"154","author":"Camilli","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_111","first-page":"562","article-title":"Management of Venous Thromboembolisms: Part, I.I. The Consensus for Pulmonary Embolism and Updates","volume":"36","author":"Wang","year":"2020","journal-title":"Acta Cardiol. Sin."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"103526","DOI":"10.1016\/j.critrevonc.2021.103526","article-title":"Factor Xa inhibitors versus low molecular weight heparin for the treatment of cancer associated venous thromboembolism; A meta-analysis of randomized controlled trials and non-randomized studies","volume":"169","author":"Hussain","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-022-01289-1","article-title":"Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Frere","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.07.029","article-title":"Treatment of Cryptogenic Stroke with Active Cancer with a New Oral Anticoagulant","volume":"26","author":"Nam","year":"2017","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejim.2022.02.020","article-title":"Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence","volume":"100","author":"Gallardo","year":"2022","journal-title":"Eur. J. Intern. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/jth.14478","article-title":"Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy: Guidance from the SSC of the ISTH","volume":"17","author":"Delluc","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"ref_117","first-page":"10","article-title":"Non-vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with atrial fibrillation","volume":"23","author":"Undas","year":"2020","journal-title":"Anatol. J. Cardiol."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Ferri, N., Colombo, E., Tenconi, M., Baldessin, L., and Corsini, A. (2022). Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14061120"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"220004","DOI":"10.1183\/16000617.0004-2022","article-title":"Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer","volume":"31","author":"Otten","year":"2022","journal-title":"Eur. Respir. Rev."},{"key":"ref_120","unstructured":"Hellfritzsch, M., Henriksen, J.N., Holt, M.I., and Grove, E.L. (2023). Seminars in Thrombosis and Hemostasis, Thieme Medical Publishers, Inc."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.thromres.2015.08.009","article-title":"Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin","volume":"136","author":"Rousseau","year":"2015","journal-title":"Thromb. Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12094-019-02263-z","article-title":"SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019)","volume":"22","year":"2020","journal-title":"Clin. Transl. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"227","DOI":"10.5694\/mja2.50004","article-title":"New guidelines from the Thrombosis and Haemostasis Society of Australia and New Zealand for the diagnosis and management of venous thromboembolism","volume":"210","author":"Tran","year":"2019","journal-title":"Med. J. Aust."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.thromres.2021.10.018","article-title":"Efficacy of primary prevention of venous thromboembolism among subgroups of cancer patients undergoing chemotherapy: A post- hoc analysis of the AVERT trial","volume":"208","author":"Nayak","year":"2021","journal-title":"Thromb. Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.thromres.2021.03.013","article-title":"Efficacy and safety of apixaban for primary prevention in gastrointestinal cancers: A post-hoc analysis of the AVERT trial","volume":"202","author":"Ladha","year":"2021","journal-title":"Thromb. Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.thromres.2022.05.014","article-title":"Efficacy and safety of apixaban for primary prevention of thromboembolism in patients with cancer and a central venous catheter: A subgroup analysis of the AVERT Trial","volume":"216","author":"Brandt","year":"2022","journal-title":"Thromb. Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.thromres.2022.01.022","article-title":"Safety and efficacy of apixaban thromboprophylaxis in ambulatory cancer patients according to renal function: A subgroup analysis of the AVERT trial","volume":"211","author":"Wang","year":"2022","journal-title":"Thromb. Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.thromres.2020.10.026","article-title":"Safety and efficacy of apixaban thromboprophylaxis in cancer patients with metastatic disease: A post-hoc analysis of the AVERT trial","volume":"197","author":"Knoll","year":"2021","journal-title":"Thromb. Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1007\/s11239-020-02317-y","article-title":"Thromboprophylaxis for patients with newly diagnosed vs. recurrent cancers: A post-hoc analysis of the avert trial","volume":"51","author":"Zhang","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"e12549","DOI":"10.1002\/rth2.12549","article-title":"Rivaroxaban thromboprophylaxis for gastric\/gastroesophageal junction tumors versus other tumors: A post hoc analysis of the randomized CASSINI trial","volume":"5","author":"Mones","year":"2021","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1055\/s-0040-1712143","article-title":"Assessing Full Benefit of Rivaroxaban Prophylaxis in High-Risk Ambulatory Patients with Cancer: Thromboembolic Events in the Randomized CASSINI Trial","volume":"4","author":"Khorana","year":"2020","journal-title":"TH Open"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"6196","DOI":"10.1002\/cam4.3269","article-title":"Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study","volume":"9","author":"McNamara","year":"2020","journal-title":"Cancer Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_134","unstructured":"National Library of Medicine (U.S.) (2023, March 15). Interaction between Direct Oral Anticoagulants and Drug-Metabolizing Enzyme Inducers. Identifier: NCT05750680, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05750680."},{"key":"ref_135","unstructured":"National Library of Medicine (U.S.) (2023, March 15). Clinical Application Model of Direct Oral Anticoagulants (MACACOD). Comprehensive Management of ACOD from a Specialized Center in Antithrombotic Therapy and Its Area of Influence Identifier: NCT04042155, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04042155."},{"key":"ref_136","unstructured":"National Library of Medicine (U.S.) (2023, March 15). Direct Oral Anticoagulants (DOACs) Versus LMWH +\/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial). Identifier: NCT02744092, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02744092."},{"key":"ref_137","unstructured":"National Library of Medicine (U.S.) (2023, March 15). VICTORIE (VTE In Cancer\u2014Treatment, Outcomes and Resource Use in Europe). Identifier: NCT04618913, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04618913."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1186\/s13063-020-04675-7","article-title":"Rivaroxaban compared to no treatment in ER-negative stage I-III early breast cancer patients (the TIP Trial): Study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial","volume":"21","author":"Castle","year":"2020","journal-title":"Trials"},{"key":"ref_139","unstructured":"National Library of Medicine (U.S.) (2023, March 15). Observational Studies in Cancer Associated Thrombosis for Rivaroxaban in Sweden (OSCAR-SE). Identifier: NCT05150938, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT05150938."},{"key":"ref_140","unstructured":"National Library of Medicine (U.S.) (2023, March 15). Primary Thromboprophylaxis in Patients with Malignancy and Central Venous Catheters: A Randomized Controlled Trial. Identifier: NCT05029063, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05029063."},{"key":"ref_141","unstructured":"National Library of Medicine (U.S.) (2023, March 15). Bleeding Risk Guided VTE Prophylaxis Strategy for Hospitalized Patients with Lung Cancer: Rationale and Design for a Multicenter, Adjudicator-Blinded, Parallel, Randomized Clinical Trial in China. Identifier: NCT04158973, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04158973."},{"key":"ref_142","unstructured":"National Library of Medicine (U.S.) (2023, March 15). Venous Thromboembolism Prevention in Outpatients with Glioma. Identifier: NCT05683808, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05683808."},{"key":"ref_143","unstructured":"National Library of Medicine (U.S.) (2023, March 15). Cost Comparison between Apixaban and Low Molecular Weight Heparin (LMWH) among Venous Thromboembolism (VTE) Cancer Patients. Identifier: NCT05643885, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05643885."},{"key":"ref_144","unstructured":"National Library of Medicine (U.S.) (2023, March 15). A Multicenter, Randomized, Open-Label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients with Cancer Associated VTE. Identifier: NCT05171049, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05171049."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.chest.2021.09.037","article-title":"Rivaroxaban vs. Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial","volume":"161","author":"Planquette","year":"2022","journal-title":"Chest"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Canonico, M.E., Santoro, C., Avvedimento, M., Giugliano, G., Mandoli, G.E., Prastaro, M., Franzone, A., Piccolo, R., Ilardi, F., and Cameli, M. (2022). Venous Thromboembolism and Cancer: A Comprehensive Review from Pathophysiology to Novel Treatment. Biomolecules, 12.","DOI":"10.3390\/biom12020259"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/10\/2697\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:32:12Z","timestamp":1760124732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/10\/2697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":147,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["cancers15102697"],"URL":"https:\/\/doi.org\/10.3390\/cancers15102697","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,10]]}}}